U.S. Cell And Gene Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, II, III, IV), By Indication (Oncology, Cardiology, CNS, Musculoskeletal, Infectious Diseases), And Segment Forecasts, 2025 - 2033

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Phase
  • 1.2.2. Indication
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Value chain based analysis (Model 2)
  • 1.7.3. Multivariate Analysis (Model 3)
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Cell and Gene Therapy Clinical Trials Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Interest in Cell and Gene Therapy
    • 3.2.1.2. Adoption of New Technology in Clinical Research
    • 3.2.1.3. Increasing Investments and R&D Funding
    • 3.2.1.4. Rising Prevalence of Rare and Genetic Disorders
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Recruitment Obstacles
• 3.3. Pricing Model Analysis
• 3.4. Technology Landscape
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Force Analysis
  • 3.5.2. PESTEL by SWOT Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. U.S. Cell and Gene Therapy Clinical Trials Market: Phase Estimates & Trend Analysis

• 4.1. U.S. Cell and Gene Therapy Clinical Trials Market, By Phase: Segment Dashboard
• 4.2. U.S. Cell and Gene Therapy Clinical Trials Market, By Phase: Movement Analysis
• 4.3. U.S. Cell and Gene Therapy Clinical Trials Market Estimates & Forecasts, By Phase, 2021 - 2033 (USD Million)
• 4.4. Phase I
  • 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Phase II
  • 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Phase III
  • 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Phase IV
  • 4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Cell and Gene Therapy Clinical Trials Market: Indication Estimates & Trend Analysis

• 5.1. U.S. Cell and Gene Therapy Clinical Trials Market, By Indication: Segment Dashboard
• 5.2. U.S. Cell and Gene Therapy Clinical Trials Market, By Indication: Movement Analysis
• 5.3. U.S. Cell and Gene Therapy Clinical Trials Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Cardiology
  • 5.5.1. Cardiology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. CNS
  • 5.6.1. CNS Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Musculoskeletal
  • 5.7.1. Musculoskeletal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Infectious diseases
  • 5.8.1. Infectious diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Dermatology
  • 5.9.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.10. Endocrine, metabolic, genetic
  • 5.10.1. Endocrine, metabolic, genetic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.11. Immunology & inflammation
  • 5.11.1. Immunology & inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.12. Ophthalmology
  • 5.12.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.13. Hematology
  • 5.13.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.14. Gastroenterology
  • 5.14.1. Gastroenterology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.15. Others
  • 5.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Market Participant Categorization
• 6.2. Company Market Share/Assessment Analysis, 2024
• 6.3. Company Profiles
  • 6.3.1. IQVIA
    • 6.3.1.1. Company Overview
    • 6.3.1.2. Financial Performance
    • 6.3.1.3. Service Benchmarking
    • 6.3.1.4. Strategic Initiatives
  • 6.3.2. ICON Plc
    • 6.3.2.1. Company Overview
    • 6.3.2.2. Financial Performance
    • 6.3.2.3. Service Benchmarking
    • 6.3.2.4. Strategic Initiatives
  • 6.3.3. LabCorp
    • 6.3.3.1. Company Overview
    • 6.3.3.2. Financial Performance
    • 6.3.3.3. Service Benchmarking
    • 6.3.3.4. Strategic Initiatives
  • 6.3.4. Charles River Laboratories
    • 6.3.4.1. Company Overview
    • 6.3.4.2. Financial Performance
    • 6.3.4.3. Service Benchmarking
    • 6.3.4.4. Strategic Initiatives
  • 6.3.5. PAREXEL International Corp.
    • 6.3.5.1. Company Overview
    • 6.3.5.2. Financial Performance
    • 6.3.5.3. Service Benchmarking
    • 6.3.5.4. Strategic Initiatives
  • 6.3.6. Syneos Health
    • 6.3.6.1. Company Overview
    • 6.3.6.2. Financial Performance
    • 6.3.6.3. Service Benchmarking
    • 6.3.6.4. Strategic Initiatives
  • 6.3.7. Medpace
    • 6.3.7.1. Company Overview
    • 6.3.7.2. Financial Performance
    • 6.3.7.3. Service Benchmarking
    • 6.3.7.4. Strategic Initiatives
  • 6.3.8. Thermo Fisher Scientific, Inc.
    • 6.3.8.1. Company Overview
    • 6.3.8.2. Financial Performance
    • 6.3.8.3. Service Benchmarking
    • 6.3.8.4. Strategic Initiatives
  • 6.3.9. Novotech
    • 6.3.9.1. Company Overview
    • 6.3.9.2. Financial Performance
    • 6.3.9.3. Service Benchmarking
    • 6.3.9.4. Strategic Initiatives
  • 6.3.10. Veristat, LLC
    • 6.3.10.1. Company Overview
    • 6.3.10.2. Financial Performance
    • 6.3.10.3. Service Benchmarking
    • 6.3.10.4. Strategic Initiatives

Chapter 7. Key Recommendations

List of Tables

• Table 1 List of Tables
• Table 2 List of Secondary Sources
• Table 3 List of Abbreviations
• Table 4 U.S. Cell And Gene Therapy Clinical Trials Market Estimates and Forecasts, By Phase, 2021 - 2033 (USD Million)
• Table 5 U.S. Cell And Gene Therapy Clinical Trials Market Estimates and Forecasts, By Indication, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Market formulation & validation
• Fig. 6 Commodity flow analysis
• Fig. 7 Value-chain-based sizing & forecasting
• Fig. 8 QFD model sizing & forecasting
• Fig. 9 Bottom-up approach
• Fig. 10 Market snapshot
• Fig. 11 Segment snapshot 1
• Fig. 12 Segment snapshot 2
• Fig. 13 Competitive landscape snapshot
• Fig. 14 Parent market outlook, 2024 (USD Billion)
• Fig. 15 Ancillary market outlook, 2024 (USD Billion)
• Fig. 16 U.S. Cell and Gene Therapy Clinical Trials Market Dynamics
• Fig. 17 Porter's five forces analysis
• Fig. 18 PESTEL analysis
• Fig. 19 U.S. Cell and Gene Therapy Clinical Trials Market: Phase outlook and key takeaways
• Fig. 20 U.S. Cell and Gene Therapy Clinical Trials Market: Phase movement analysis
• Fig. 21 Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 22 Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 23 Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 24 Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 25 U.S. Cell and Gene Therapy Clinical Trials Market: Indication outlook and key takeaways
• Fig. 26 U.S. Cell and Gene Therapy Clinical Trials Market: Indication movement analysis
• Fig. 27 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 28 Cardiology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 29 CNS Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 30 Musculoskeletal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 31 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 32 Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 33 Endocrine, metabolic, genetic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 34 Immunology & Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 35 Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 36 Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 37 Gastroenterology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 38 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 39 Key company categorization
• Fig. 40 Service heat map analysis
• Fig. 41 Strategic framework